Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 21;119(2):349-359.
doi: 10.1016/j.bpj.2020.05.033. Epub 2020 Jun 10.

The Effect of (-)-Epigallocatechin-3-Gallate on the Amyloid-β Secondary Structure

Affiliations
Free PMC article

The Effect of (-)-Epigallocatechin-3-Gallate on the Amyloid-β Secondary Structure

Atanu Acharya et al. Biophys J. .
Free PMC article

Abstract

Amyloid-β (Aβ) is a macromolecular structure of great interest because its misfolding and aggregation, along with changes in the secondary structure, have been correlated with its toxicity in various neurodegenerative diseases. Small drug-like molecules can modulate the amyloid secondary structure and therefore have raised significant interest in applications to active and passive therapies targeting amyloids. In this study, we investigate the interactions of epigallocatechin-3-gallate (EGCG), found in green tea, with Aβ polypeptides, using a combination of in vitro immuno-infrared sensor measurements, docking, molecular dynamics simulations, and ab initio calculations. We find that the interactions of EGCG are dominated by only a few residues in the fibrils, including hydrophobic π-π interactions with aromatic rings of side chains and hydrophilic interactions with the backbone of Aβ, as confirmed by extended (1-μs-long) molecular dynamics simulations. Immuno-infrared sensor data are consistent with degradation of Aβ fibril induced by EGCG and inhibition of Aβ fibril and oligomer formation, as manifested by the recovery of the amide-I band of monomeric Aβ, which is red-shifted by 26 cm-1 when compared to the amide-I band of the fibrillar form. The shift is rationalized by computations of the infrared spectra of Aβ42 model structures, suggesting that the conformational change involves interchain hydrogen bonds in the amyloid fibrils that are broken upon binding of EGCG.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Illustration of fragmentation procedure for model (A) dimeric and (B) monomeric Aβ. Each fragment contains five amino acids and thus includes all possible intrachain H-bonding observed in a helical structure. The hydrogen-bonding network in (C) monomeric and (D) dimeric fibril (bottom) models is shown. Individual amino acids are shown in different colors. (E) Illustration of the setup for the divide-and-conquer approach and representation of an individual fragment subjected to partial optimization and the subsequent frequency calculation are shown. To see this figure in color, go online.
Figure 2
Figure 2
Experimental IR spectra of monomeric (red) and fibrillar Aβ42 (blue) measured directly after 0 min. The peak of the absorption band of fibrillar Aβ42 at 1628 cm−1 corresponds to the amide-I stretching vibrational mode of β-sheets, which is at 1630 cm−1 (31,51), indicating that Aβ42 fibrils are actually immobilized on the sensor surface. The peak of monomeric Aβ42 at 1654 cm−1 corresponds to the amide-I stretching vibrational mode of helical or coil secondary structure, indicating a nonfibrillar structure. To see this figure in color, go online.
Figure 3
Figure 3
(A) Spectra of fibrillar Aβ42 after immobilization on the immuno-infrared sensor and treatment with EGCG for 1 day. (B) Spectra of preincubated monomeric Aβ with EGCG, which prevents the formation of fibrillar species, are shown. The concentrations of Aβ fibril, monomer, and EGCG in (A) and (B) were 36, 36, and 320 nM, respectively. (C) Spectra corresponding to the evolution of Aβ42 fibrils from monomers in the absence of EGCG are shown. (D) The chemical structure of EGCG is shown. To see this figure in color, go online.
Figure 4
Figure 4
(A) EGCG binding sites (numbered 1–3) in Aβ42 with respective docking scores. Aβ42 is shown in surface representation and colored by residue type: hydrophobic (white), acidic (red), basic (blue), and polar (green). EGCG molecules in each site are shown in van der Waals representation. (B) Interacting residues of Aβ42 with EGCG in each docking pose are shown. To see this figure in color, go online.
Figure 5
Figure 5
Representative figures of EGCG occupying (A) site #1 and site #4, (B) site #2 and site #4, and (C) site #3 and site #4. (D) The relative populations of the docking sites from MD simulation are shown. The populations are grouped by their site numbers. Aβ42 is colored by residue type: hydrophobic (white), acidic (red), basic (blue), and polar (green). EGCG molecules are shown in van der Waals representation. To see this figure in color, go online.
Figure 6
Figure 6
Dimer models of fibrillar A used in the divide-and-conquer approach from four different PDB entries: (A) 2BEG, (B) 5OQV, (C) 2MXU, and (D) 2NAO. (E) Partial disruption of interchain hydrogen bonding observed for one of the structures used for computation is shown. The relevant residues are annotated in red, and the α-carbons of those residues are shown as red spheres. To see this figure in color, go online.
Figure 7
Figure 7
Analysis of the computed IR spectra in the 1600–1700 cm−1 region. (A) Comparison of IR spectra of all the fibril models is shown. (B) A comparison of IR spectra of 2NAO structure with and without the broken interchain hydrogen-bonding residues is shown. To see this figure in color, go online.
Figure 8
Figure 8
Comparison of the computed amide-I band in monomeric (orange) and dimeric Aβ42 (blue) in β-enriched structures. IR spectrum of monomeric Aβ42 (red) is also shown for reference. To see this figure in color, go online.

Similar articles

Cited by

References

    1. Alzheimer’s Association 2018 Alzheimer’s disease facts and figures. Alzheimers Dement. 2018;14:367–429.
    1. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356. - PubMed
    1. Dohler F., Sepulveda-Falla D., Glatzel M. High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer’s disease. Brain. 2014;137:873–886. - PubMed
    1. Teplow D.B., Lazo N.D., Stanley H.E. Elucidating amyloid β-protein folding and assembly: a multidisciplinary approach. Acc. Chem. Res. 2006;39:635–645. - PubMed
    1. Mousseau N., Derreumaux P. Exploring the early steps of amyloid peptide aggregation by computers. Acc. Chem. Res. 2005;38:885–891. - PubMed

Publication types